Tesamorelin vs CJC-1295 (2026): Evidence & Regulatory Status Compared

Tesamorelin and CJC-1295 are both GHRH analogs that raise growth hormone, but they sit on opposite sides of the approval line. Tesamorelin is an FDA-approved drug (Egrifta) for HIV-associated lipodystrophy, backed by randomized controlled trials. CJC-1295 is an unapproved research peptide with only early-phase human pharmacology data and no controlled trials for the uses it is marketed for. Both are prohibited in sport. Research information only, not medical advice.

Last updated:

Independent information index. We do not sell vendor placements or take affiliate commissions on peptide sales. Read our affiliate disclosure .

Tesamorelin CJC-1295
Peptide class GHRH analog (approved drug) Long-acting GHRH analog (research peptide)
Evidence level (highest) Randomized controlled trials (HIV-associated lipodystrophy) Early-phase human pharmacology, otherwise preclinical
US drug approval status FDA-approved (Egrifta 2010; Egrifta SV 2019; Egrifta WR 2025) Unapproved drug
Approved indication Excess visceral abdominal fat in adults with HIV-associated lipodystrophy None — not approved for any indication
FDA 503A compounding Approved drug; not a compounding-list peptide Removed from Category 2 (Apr 2026); under PCAC review, not compoundable
WADA status Prohibited (S2, growth-hormone releasing factors) Prohibited (S2, growth-hormone releasing factors)
EU marketing authorization None None

Verdict

These two are the clearest illustration in the peptide space of what "FDA-approved" actually buys. Tesamorelin and CJC-1295 are both GHRH analogs that raise growth hormone, but Tesamorelin went through randomized controlled trials and is an approved drug for a specific indication — excess visceral abdominal fat in adults with HIV-associated lipodystrophy — while CJC-1295 has only early-phase human pharmacology data and no controlled trials for the anti-aging and body-composition uses it is sold for. They are not interchangeable: one is a regulated medicine with a narrow label, the other is a research-only peptide in regulatory limbo. Both are banned in sport. Outside Tesamorelin's approved indication, neither has the controlled human evidence to call it a proven therapeutic.

Tesamorelin and CJC-1295 get compared because they do the same biochemical thing — both are GHRH analogs that stimulate growth-hormone release. But the comparison is really about a single dividing line in the peptide world: one of them is an approved drug and the other is not. The table above is the row-by-row breakdown. Below is what each row means.

Tesamorelin vs CJC-1295: the short version

Tesamorelin is an FDA-approved medication (Egrifta) for excess visceral abdominal fat in adults with HIV-associated lipodystrophy, supported by randomized controlled trials. CJC-1295 is an unapproved research peptide with early-phase human pharmacology data and no controlled trials for the uses it is marketed for. Same drug class, opposite sides of the approval line.

Evidence: an approved label vs early pharmacology

This is the heart of it. Tesamorelin’s development included randomized controlled trials in HIV-associated lipodystrophy that were strong enough to earn FDA approval, and the formulation has since been updated (Egrifta SV, then the F8 formulation Egrifta WR approved in 2025). CJC-1295’s human record is early-phase pharmacology — it raises growth-hormone and IGF-1 — without controlled trials of the anti-aging or body-composition outcomes it is sold for. For how we weigh these tiers, see our how we grade evidence explainer, the full Tesamorelin evidence and regulatory record, and the CJC-1295 evidence and regulatory record.

Regulation: approved drug vs compounding limbo

Tesamorelin is a regulated medicine with an FDA label; its F8 formulation, Egrifta WR, was approved in 2025. CJC-1295 is the opposite case: per Frier Levitt it was removed from the FDA 503A “do not compound” Category 2 list in April 2026 but is not eligible for compounding and remains under PCAC review. In sport, both are prohibited at all times under the WADA S2 category for growth-hormone-releasing factors.

So which one, if either?

If the interest is the approved indication — visceral fat in HIV-associated lipodystrophy — Tesamorelin is the only one of the two that is a regulated, evidenced option, and that is a decision for a physician. For the general anti-aging and performance uses both are marketed for, neither has controlled human evidence, and CJC-1295 in particular remains research-only and unapproved.

Research information only. This page is not medical advice. Tesamorelin is a prescription drug; talk to a licensed physician before considering any peptide.

FAQ

Is Tesamorelin or CJC-1295 FDA approved?
Tesamorelin is FDA-approved (as Egrifta, Egrifta SV and Egrifta WR) to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. CJC-1295 is not approved for any indication; it was removed from the FDA "do not compound" Category 2 list in April 2026 but remains under Pharmacy Compounding Advisory Committee review and is not compoundable.
Are they the same kind of peptide?
Both are GHRH analogs that stimulate growth-hormone release, which is why they get compared. The decisive difference is evidence and approval: Tesamorelin has randomized controlled trials and an FDA label; CJC-1295 has early-phase pharmacology data and no controlled trials for its marketed uses.
Are they allowed in sport?
No. Growth-hormone-releasing factors, including both Tesamorelin and CJC-1295, are prohibited at all times under WADA category S2. This page is research information, not medical or legal advice.

Sources